<DOC>
	<DOCNO>NCT01250548</DOCNO>
	<brief_summary>The purpose study compare effect apremilast placebo ( inactive substance look like apremilast ) people rheumatoid arthritis . The investigator collect information study help u determine - - safety apremilast patient active rheumatoid arthritis - long take patient active rheumatoid arthritis respond apremilast - long effect apremilast last treatment end .</brief_summary>
	<brief_title>The Controlled Trial Apremilast Rheumatoid Arthritis Treatment ( CARAT )</brief_title>
	<detailed_description>Many manifestation associate RA result , significantly influence , effect pro-inflammatory cytokine ( e.g. , TNF , IL-1 , IL-6 ) . Specific inhibition cytokine newer , parenterally administer biologic agent revolutionize treatment RA . Apremilast novel , orally administer drug approach reduction pro-inflammatory cytokine via inhibition phosphodiesterase type 4 ( PDE4 ) . Apremilast , Acetamide , N- [ 2- [ ( 1S ) -1- ( 3-ethoxy-4-methoxyphenyl ) -2- ( methylsulfonyl ) ethyl ] -2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl ] phosphodiesterase type 4 ( PDE4 ) inhibitor development use treatment inflammatory condition . PDE4 one major phosphodiesterases express leukocyte . Inhibitors PDE4 cause accumulation intracellular cyclic adenosine monophosphate ( cAMP ) , turn activates protein kinase A downstream effector , result inhibition pro-inflammatory cytokine transcription cellular response neutrophil degranulation , chemotaxis , adhesion endothelial cell . In human cellular model , apremilast inhibited production inflammatory mediator TNF-α , IL-12 , IL-2 , IFN-γ , IL-5 , IL-8 , leukotriene B4 ( LTB4 ) , adhesion molecule CD18/CD11b ( Mac-1 ) . Apremilast also show potent anti-inflammatory agent several animal model inflammation .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Must able adhere study visit schedule protocol requirement document rheumatoid arthritis ( RA ) diagnosis 1987 American College Rheumatology ( ACR ) criteria least 6 month disease duration 6 month ( symptom onset ) fail 1 DMARD active RA despite current DMARD therapy ; active disease define 4 tender 4 swollen joint ( 28 joint examine ) one following : ESR 28 high mm/hr ; CRP 1.0 mg/dl ; Morning stiffness 45 minute . Patients receive DMARD biologic therapy must undergo drug washout . Patients receive nonsteroidal antiinflammatory drug ( NSAID ) and/or prednisone ( 10 less mg day ) must stable dos agent 2 week . Must meet laboratory criterion specify protocol Females childbearing potential ( FCBP ) must negative urine pregnancy test screening must adhere adequate form contraception define protocol . Must agree pregnancy test every 28 day study medication . Males ( include vasectomy ) must agree use barrier contraception ( latex condom ) engage sexual activity FCBP study medication 28 day take last dose study medication Inability provide voluntary consent History clinically significant cardiac , endocrinologic , pulmonary , neurologic , psychiatric , hepatic , renal , hematologic , neurologic , gastrointestinal , immunologic , major disease Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study Pregnant breastfeed female Systemic fungal infection Active tuberculosis ( TB ) history incompletely treated tuberculosis . History recurrent bacterial infection ( least 3 major infection result hospitalization and/or require intravenous antibiotic treatment within past 2 year ) Clinically significant abnormality chest xray ( CXR ) screening . Chest xrays perform within 3 month prior start study drug acceptable . Use investigational medication within 28 day prior randomization 5 halflives know ( whichever longer ) Any clinically significant abnormality 12lead ECG screen History congenital acquire immunodeficiency ( eg , Common Variable Immunodeficiency [ CVID ] ) History Human Immunodeficiency Virus ( HIV ) infection Presence hepatitis B surface antigen ( HBsAg ) Hepatitis core antibody positive screening . Antibodies Hepatitis C virus screen History malignancy within 5 year prior screen visit ( except treat [ i.e . cure ] basal cell skin carcinoma treat [ i.e . cure ] carcinoma situ cervix ) currently DMARD therapy currently take biologics treat rituximab last 6 month Recent hospitalization ( last 3 month ) Planned pregnancy major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>RA</keyword>
	<keyword>Active rheumatoid arthritis</keyword>
</DOC>